Literature DB >> 9234742

Opposite effects of the acute promyelocytic leukemia PML-retinoic acid receptor alpha (RAR alpha) and PLZF-RAR alpha fusion proteins on retinoic acid signalling.

M Ruthardt1, U Testa, C Nervi, P F Ferrucci, F Grignani, E Puccetti, F Grignani, C Peschle, P G Pelicci.   

Abstract

Fusion proteins involving the retinoic acid receptor alpha (RAR alpha) and the PML or PLZF nuclear protein are the genetic markers of acute promyelocytic leukemias (APLs). APLs with the PML-RAR alpha or the PLZF-RAR alpha fusion protein are phenotypically indistinguishable except that they differ in their sensitivity to retinoic acid (RA)-induced differentiation: PML-RAR alpha blasts are sensitive to RA and patients enter disease remission after RA treatment, while patients with PLZF-RAR alpha do not. We here report that (i) like PML-RAR alpha expression, PLZF-RAR alpha expression blocks terminal differentiation of hematopoietic precursor cell lines (U937 and HL-60) in response to different stimuli (vitamin D3, transforming growth factor beta1, and dimethyl sulfoxide); (ii) PML-RAR alpha, but not PLZF-RAR alpha, increases RA sensitivity of hematopoietic precursor cells and restores RA sensitivity of RA-resistant hematopoietic cells; (iii) PML-RAR alpha and PLZF-RAR alpha have similar RA binding affinities; and (iv) PML-RAR alpha enhances the RA response of RA target genes (those for RAR beta, RAR gamma, and transglutaminase type II [TGase]) in vivo, while PLZF-RAR alpha expression has either no effect (RAR beta) or an inhibitory activity (RAR gamma and type II TGase). These data demonstrate that PML-RAR alpha and PLZF-RAR alpha have similar (inhibitory) effects on RA-independent differentiation and opposite (stimulatory or inhibitory) effects on RA-dependent differentiation and that they behave in vivo as RA-dependent enhancers or inhibitors of RA-responsive genes, respectively. Their different activities on the RA signalling pathway might underlie the different responses of PML-RAR alpha and PLZF-RAR alpha APLs to RA treatment. The PLZF-RAR alpha fusion protein contains an approximately 120-amino-acid N-terminal motif (called the POZ domain), which is also found in a variety of zinc finger proteins and a group of poxvirus proteins and which mediates protein-protein interactions. Deletion of the PLZF POZ domain partially abrogated the inhibitory effect of PLZF-RAR alpha on RA-induced differentiation and on RA-mediated type II TGase up-regulation, suggesting that POZ-mediated protein interactions might be responsible for the inhibitory transcriptional activities of PLZF-RAR alpha.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9234742      PMCID: PMC232338          DOI: 10.1128/MCB.17.8.4859

Source DB:  PubMed          Journal:  Mol Cell Biol        ISSN: 0270-7306            Impact factor:   4.272


  51 in total

1.  Treatment of first relapse in acute promyelocytic leukaemia with all-trans retinoic acid.

Authors:  L Degos; C Chomienne; M T Daniel; R Berger; H Dombret; P Fenaux; S Castaigne
Journal:  Lancet       Date:  1990-12-08       Impact factor: 79.321

2.  Isolation and binding characteristics of nuclear retinoic acid receptors.

Authors:  A M Jetten; J F Grippo; C Nervi
Journal:  Methods Enzymol       Date:  1990       Impact factor: 1.600

Review 3.  The HL-60 promyelocytic leukemia cell line: proliferation, differentiation, and cellular oncogene expression.

Authors:  S J Collins
Journal:  Blood       Date:  1987-11       Impact factor: 22.113

4.  Molecular evaluation of response to all-trans-retinoic acid therapy in patients with acute promyelocytic leukemia.

Authors:  F Lo Coco; G Avvisati; D Diverio; M C Petti; M Alcalay; P P Pandolfi; D Zangrilli; A Biondi; A Rambaldi; M L Moleti
Journal:  Blood       Date:  1991-04-15       Impact factor: 22.113

5.  The PML-RAR alpha fusion mRNA generated by the t(15;17) translocation in acute promyelocytic leukemia encodes a functionally altered RAR.

Authors:  H de Thé; C Lavau; A Marchio; C Chomienne; L Degos; A Dejean
Journal:  Cell       Date:  1991-08-23       Impact factor: 41.582

6.  Chromosomal translocation t(15;17) in human acute promyelocytic leukemia fuses RAR alpha with a novel putative transcription factor, PML.

Authors:  A Kakizuka; W H Miller; K Umesono; R P Warrell; S R Frankel; V V Murty; E Dmitrovsky; R M Evans
Journal:  Cell       Date:  1991-08-23       Impact factor: 41.582

7.  Structure and origin of the acute promyelocytic leukemia myl/RAR alpha cDNA and characterization of its retinoid-binding and transactivation properties.

Authors:  P P Pandolfi; F Grignani; M Alcalay; A Mencarelli; A Biondi; F LoCoco; F Grignani; P G Pelicci
Journal:  Oncogene       Date:  1991-07       Impact factor: 9.867

8.  Use of all-trans retinoic acid in the treatment of acute promyelocytic leukemia.

Authors:  M E Huang; Y C Ye; S R Chen; J R Chai; J X Lu; L Zhoa; L J Gu; Z Y Wang
Journal:  Blood       Date:  1988-08       Impact factor: 22.113

9.  Differentiation therapy of acute promyelocytic leukemia with tretinoin (all-trans-retinoic acid).

Authors:  R P Warrell; S R Frankel; W H Miller; D A Scheinberg; L M Itri; W N Hittelman; R Vyas; M Andreeff; A Tafuri; A Jakubowski
Journal:  N Engl J Med       Date:  1991-05-16       Impact factor: 91.245

10.  A retinoic acid response element is present in the mouse cellular retinol binding protein I (mCRBPI) promoter.

Authors:  W C Smith; H Nakshatri; P Leroy; J Rees; P Chambon
Journal:  EMBO J       Date:  1991-08       Impact factor: 11.598

View more
  23 in total

1.  Co-operative DNA binding by GAGA transcription factor requires the conserved BTB/POZ domain and reorganizes promoter topology.

Authors:  K R Katsani; M A Hajibagheri; C P Verrijzer
Journal:  EMBO J       Date:  1999-02-01       Impact factor: 11.598

2.  DNA recognition by the aberrant retinoic acid receptors implicated in human acute promyelocytic leukemia.

Authors:  H Hauksdóttir; M L Privalsky
Journal:  Cell Growth Differ       Date:  2001-02

3.  Genomic sequence, structural organization, molecular evolution, and aberrant rearrangement of promyelocytic leukemia zinc finger gene.

Authors:  T Zhang; H Xiong; L X Kan; C K Zhang; X F Jiao; G Fu; Q H Zhang; L Lu; J H Tong; B W Gu; M Yu; J X Liu; J Licht; S Waxman; A Zelent; E Chen; S J Chen
Journal:  Proc Natl Acad Sci U S A       Date:  1999-09-28       Impact factor: 11.205

4.  CCAAT/enhancer binding protein epsilon is a potential retinoid target gene in acute promyelocytic leukemia treatment.

Authors:  D J Park; A M Chumakov; P T Vuong; D Y Chih; A F Gombart; W H Miller; H P Koeffler
Journal:  J Clin Invest       Date:  1999-05-15       Impact factor: 14.808

5.  8-CPT-cAMP/all-trans retinoic acid targets t(11;17) acute promyelocytic leukemia through enhanced cell differentiation and PLZF/RARα degradation.

Authors:  Bo Jiao; Zhi-Hong Ren; Ping Liu; Li-Juan Chen; Jing-Yi Shi; Ying Dong; Julien Ablain; Lin Shi; Li Gao; Jun-Pei Hu; Rui-Bao Ren; Hugues de Thé; Zhu Chen; Sai-Juan Chen
Journal:  Proc Natl Acad Sci U S A       Date:  2013-02-04       Impact factor: 11.205

6.  C/EBPbeta: a major PML-RARA-responsive gene in retinoic acid-induced differentiation of APL cells.

Authors:  Estelle Duprez; Katharina Wagner; Heike Koch; Daniel G Tenen
Journal:  EMBO J       Date:  2003-11-03       Impact factor: 11.598

7.  The promyelocytic leukemia zinc finger protein affects myeloid cell growth, differentiation, and apoptosis.

Authors:  R Shaknovich; P L Yeyati; S Ivins; A Melnick; C Lempert; S Waxman; A Zelent; J D Licht
Journal:  Mol Cell Biol       Date:  1998-09       Impact factor: 4.272

8.  Acute myeloid leukemia fusion proteins deregulate genes involved in stem cell maintenance and DNA repair.

Authors:  Myriam Alcalay; Natalia Meani; Vania Gelmetti; Anna Fantozzi; Marta Fagioli; Annette Orleth; Daniela Riganelli; Carla Sebastiani; Enrico Cappelli; Cristina Casciari; Maria Teresa Sciurpi; Angela Rosa Mariano; Simone Paolo Minardi; Lucilla Luzi; Heiko Muller; Pier Paolo Di Fiore; Guido Frosina; Pier Giuseppe Pelicci
Journal:  J Clin Invest       Date:  2003-12       Impact factor: 14.808

9.  The PRC1 Polycomb group complex interacts with PLZF/RARA to mediate leukemic transformation.

Authors:  Hanane Boukarabila; Andrew J Saurin; Eric Batsché; Noushine Mossadegh; Maarten van Lohuizen; Arie P Otte; Jacques Pradel; Christian Muchardt; Michael Sieweke; Estelle Duprez
Journal:  Genes Dev       Date:  2009-05-15       Impact factor: 11.361

10.  Comprehensive genomic screens identify a role for PLZF-RARalpha as a positive regulator of cell proliferation via direct regulation of c-MYC.

Authors:  Kim L Rice; Itsaso Hormaeche; Sergei Doulatov; Jared M Flatow; David Grimwade; Ken I Mills; Magdalena Leiva; Julien Ablain; Charuta Ambardekar; Melanie J McConnell; John E Dick; Jonathan D Licht
Journal:  Blood       Date:  2009-10-23       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.